| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/NM0697-632 |
| P698 | PubMed publication ID | 9176489 |
| P50 | author | Galina Selivanova | Q50923870 |
| Klas Wiman | Q57419790 | ||
| P2093 | author name string | B Groner | |
| M Ström | |||
| I Okan | |||
| M Fritsche | |||
| R C Grafström | |||
| V Iotsova | |||
| P2860 | cites work | Tight control of gene expression in mammalian cells by tetracycline-responsive promoters | Q24564850 |
| Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations | Q27730815 | ||
| Oncogenic forms of p53 inhibit p53-regulated gene expression | Q28251120 | ||
| Allosteric activation of latent p53 tetramers | Q28623087 | ||
| Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours | Q29547697 | ||
| Suppression of human colorectal carcinoma cell growth by wild-type p53 | Q29618318 | ||
| Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms | Q29618586 | ||
| Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6 | Q29622924 | ||
| Conformational shifts propagate from the oligomerization domain of p53 to its tetrameric DNA binding domain and restore DNA binding to select p53 mutants. | Q38313400 | ||
| The single-stranded DNA end binding site of p53 coincides with the C-terminal regulatory region. | Q38353041 | ||
| Activation of the cryptic DNA binding function of mutant forms of p53. | Q40408305 | ||
| The Retro-inverso Form of a Homeobox-Derived Short Peptide Is Rapidly Internalized by Cultured Neurons: A New Basis for an Efficient Intracellular Delivery System | Q54162483 | ||
| Small peptides activate the latent sequence-specific DNA binding function of p53. | Q54601436 | ||
| Structure-based rescue of common tumor-derived p53 mutants | Q71607067 | ||
| p53-dependent apoptosis suppresses tumor growth and progression in vivo | Q72149266 | ||
| p53 status and the efficacy of cancer therapy in vivo | Q72839445 | ||
| P4510 | describes a project that uses | synthetic peptide | Q104631433 |
| P433 | issue | 6 | |
| P304 | page(s) | 632-638 | |
| P577 | publication date | 1997-06-01 | |
| P1433 | published in | Nature Medicine | Q1633234 |
| P1476 | title | Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain | |
| P478 | volume | 3 |
| Q37535193 | A novel cell-penetrating peptide derived from WT1 enhances p53 activity, induces cell senescence and displays antimelanoma activity in xeno- and syngeneic systems. |
| Q24530763 | A peptide that binds and stabilizes p53 core domain: chaperone strategy for rescue of oncogenic mutants |
| Q36601373 | Acetylation of p53 augments its site-specific DNA binding both in vitro and in vivo |
| Q28366563 | Activation and activities of the p53 tumour suppressor protein |
| Q27860534 | Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain |
| Q23920106 | Activation of targeted necrosis by a p53 peptide: a novel death pathway that circumvents apoptotic resistance |
| Q37186976 | Aging-associated truncated form of p53 interacts with wild-type p53 and alters p53 stability, localization, and activity |
| Q30868722 | Allosteric drugs: thinking outside the active-site box. |
| Q45880404 | An evolutionary-game model of tumour-cell interactions: possible relevance to gene therapy |
| Q41737530 | Apoptosis by p53: mechanisms, regulation, and clinical implications |
| Q36017772 | Apoptosis-based therapies and drug targets |
| Q34570100 | Assessing TP53 status in human tumours to evaluate clinical outcome |
| Q35014385 | Awakening guardian angels: drugging the p53 pathway |
| Q64257608 | Beyond EGFR Targeting in SCCHN: Angiogenesis, PI3K, and Other Molecular Targets |
| Q57890248 | Bioactive Natural Peptides |
| Q38974301 | Building Cell Selectivity into CPP-Mediated Strategies |
| Q24800091 | CP-31398, a putative p53-stabilizing molecule tested in mammalian cells and in yeast for its effects on p53 transcriptional activity |
| Q41997461 | Cell penetrating peptides to dissect host-pathogen protein-protein interactions in Theileria-transformed leukocytes |
| Q73212113 | Conformational and molecular basis for induction of apoptosis by a p53 C-terminal peptide in human cancer cells |
| Q23924041 | Correlation between hydrophobic properties and efficiency of carrier-mediated membrane transduction and apoptosis of a p53 C-terminal peptide |
| Q38112074 | Current understanding of the role and targeting of tumor suppressor p53 in glioblastoma multiforme |
| Q40105893 | Cytotoxic drug-induced, p53-mediated upregulation of caspase-8 in tumor cells |
| Q26799856 | Depot-Based Delivery Systems for Pro-Angiogenic Peptides: A Review |
| Q73073429 | Design and characterization of a hyperstable p16INK4a that restores Cdk4 binding activity when combined with oncogenic mutations |
| Q28386022 | Design and implementation of a high yield production system for recombinant expression of peptides |
| Q35246152 | Development and in vitro assessment of enzymatically-responsive poly(ethylene glycol) hydrogels for the delivery of therapeutic peptides |
| Q77291051 | Differentiation and reversal of malignant changes in colon cancer through PPARgamma |
| Q33859300 | Discovering novel chemotherapeutic drugs for the third millennium |
| Q73155202 | Downregulation of telomerase reverse transcriptase mRNA expression by wild type p53 in human tumor cells |
| Q28077156 | Emerging Non-Canonical Functions and Regulation by p53: p53 and Stemness |
| Q37134828 | Engineering Salmonella as intracellular factory for effective killing of tumour cells. |
| Q48025794 | Features of replicative senescence induced by direct addition of antennapedia-p16INK4A fusion protein to human diploid fibroblasts |
| Q34348315 | Gene therapy for gastric cancer: problems and prospects |
| Q41037063 | Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations |
| Q24791259 | Glycerol restores heat-induced p53-dependent apoptosis of human glioblastoma cells bearing mutant p53 |
| Q38306067 | Glycerol restores p53-dependent radiosensitivity of human head and neck cancer cells bearing mutant p53. |
| Q64244585 | HEXIM1 Peptide Exhibits Antimicrobial Activity Against Antibiotic Resistant Bacteria Through Guidance of Cell Penetrating Peptide |
| Q34353830 | Hsp70 interactions with the p53 tumour suppressor protein |
| Q37379743 | Identification of an additional negative regulatory region for p53 sequence-specific DNA binding |
| Q35043420 | Induction of apoptosis in cancer: new therapeutic opportunities |
| Q36545877 | Inhibiting bladder tumor growth with a cell penetrating R11 peptide derived from the p53 C-terminus |
| Q38796979 | Inhibition of cell proliferation, migration and invasion by a glioma-targeted fusion protein combining the p53 C terminus and MDM2-binding domain |
| Q36777338 | Interactions of mutant p53 with DNA: guilt by association |
| Q33255210 | JAZ mediates G1 cell-cycle arrest and apoptosis by positively regulating p53 transcriptional activity |
| Q47786180 | Keeping an old friend under control: regulation of p53 stability |
| Q31926029 | Key targets for the execution of radiation-induced tumor cell apoptosis: the role of p53 and caspases |
| Q53399551 | Knock-in mice with a chimeric human/murine p53 gene develop normally and show wild-type p53 responses to DNA damaging agents: a new biomedical research tool. |
| Q73713259 | Mdm2 binding to a conformationally sensitive domain on p53 can be modulated by RNA |
| Q47416965 | Mechanisms of transcriptional regulation by p53. |
| Q38235124 | Mitochondria-mediated apoptosis in mammals |
| Q72993916 | Molecular evolution of the thermosensitive PAb1620 epitope of human p53 by DNA shuffling |
| Q36661775 | Mutant p53 proteins: between loss and gain of function |
| Q41968106 | Mutant p53 targeting by the low molecular weight compound STIMA-1 |
| Q26770576 | Mutant p53: One, No One, and One Hundred Thousand |
| Q36070574 | Mutant p53: one name, many proteins |
| Q74631439 | NMR spectroscopy reveals the solution dimerization interface of p53 core domains bound to their consensus DNA |
| Q45856234 | New p53-based anti-cancer therapeutic strategies |
| Q40938040 | Novel phosphorylation sites of human tumour suppressor protein p53 at Ser20 and Thr18 that disrupt the binding of mdm2 (mouse double minute 2) protein are modified in human cancers |
| Q51836900 | Nuclear delivery of p53 C-terminal peptides into cancer cells using scFv fragments of a monoclonal antibody that penetrates living cells. |
| Q38212609 | Oncoapoptotic markers in oral cancer: prognostics and therapeutic perspective |
| Q34539978 | P53: an ubiquitous target of anticancer drugs |
| Q33931980 | Pathologies associated with the p53 response |
| Q56895493 | Peptides derived from the two regulatory domains of p53 are recognized by two p53-activating antibodies |
| Q23918117 | Peptides from the amino terminal mdm-2-binding domain of p53, designed from conformational analysis, are selectively cytotoxic to transformed cells |
| Q38314197 | Precise characterisation of monoclonal antibodies to the C-terminal region of p53 protein using the PEPSCAN ELISA technique and a new non-radioactive gel shift assay |
| Q46715568 | Prognostic relevance of p53 and bcl-2 immunoreactivity for early invasive pT1/pT2 gastric carcinomas: indicators for limited gastric resections? |
| Q35154009 | Protection against ovariectomy-induced bone loss by tranilast. |
| Q35116243 | Proteomics: a strategy to understand the novel targets in protein misfolding and cancer therapy |
| Q36804413 | RING finger protein 31 promotes p53 degradation in breast cancer cells |
| Q39445499 | Reactivation of mutant p53 through interaction of a C-terminal peptide with the core domain. |
| Q36777373 | Reactivation of mutant p53: molecular mechanisms and therapeutic potential |
| Q34498137 | Recognition of RNA by the p53 tumor suppressor protein in the yeast three-hybrid system |
| Q30872181 | Recruitment of AtWHY1 and AtWHY3 by a distal element upstream of the kinesin gene AtKP1 to mediate transcriptional repression. |
| Q33807801 | Regulation of p53 in response to DNA damage |
| Q30329984 | Rescuing the function of mutant p53. |
| Q36733743 | Restoration of DNA-binding and growth-suppressive activity of mutant forms of p53 via a PCAF-mediated acetylation pathway |
| Q31041084 | Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. |
| Q38328861 | Restoration of transcriptional activity of p53 mutants in human tumour cells by intracellular expression of anti-p53 single chain Fv fragments |
| Q40747748 | Restoration of wild-type conformation and activity of a temperature-sensitive mutant of p53 (p53(V272M)) by the cytoprotective aminothiol WR1065 in the esophageal cancer cell line TE-1. |
| Q36710840 | Restoration of wild-type p53 function in human cancer: relevance for tumor therapy. |
| Q30831001 | Restoration of wild-type p53 function in human tumors: strategies for efficient cancer therapy. |
| Q37818291 | Restoring p53 tumor suppressor activity as an anticancer therapeutic strategy |
| Q23924040 | Selective induction of apoptosis through the FADD/caspase-8 pathway by a p53 c-terminal peptide in human pre-malignant and malignant cells |
| Q33833881 | Senescent cells as a source of inflammatory factors for tumor progression |
| Q35204556 | Small molecules that reactivate mutant p53. |
| Q34076012 | Strategies for manipulating the p53 pathway in the treatment of human cancer. |
| Q34687279 | Suppression of glucosylceramide synthase restores p53-dependent apoptosis in mutant p53 cancer cells |
| Q24534295 | Suppression of the STK15 oncogenic activity requires a transactivation-independent p53 function |
| Q36868764 | TAT-mediated intracellular delivery of NPM-derived peptide induces apoptosis in leukemic cells and suppresses leukemogenesis in mice |
| Q34125637 | TBX2 and TBX3: the special value for anticancer drug targets. |
| Q34568607 | TP53: a key gene in human cancer. |
| Q26770856 | Targeting Oncogenic Mutant p53 for Cancer Therapy |
| Q47291772 | Targeting mutant p53 for efficient cancer therapy. |
| Q33655329 | Targeting p53 for Novel Anticancer Therapy |
| Q24556628 | The C terminus of p53 family proteins is a cell fate determinant |
| Q91816686 | The Diverse Functions of Mutant 53, Its Family Members and Isoforms in Cancer |
| Q38186535 | The aggregation of mutant p53 produces prion-like properties in cancer |
| Q34980881 | The chemical biology of apoptosis. Exploring protein-protein interactions and the life and death of cells with small molecules |
| Q34402080 | The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth |
| Q34989790 | The genetic pathogenesis of colorectal cancer |
| Q27686765 | The rebel angel: mutant p53 as the driving oncogene in breast cancer |
| Q29620106 | The senescence-associated secretory phenotype: the dark side of tumor suppression |
| Q37081504 | The use of p53 as a tool for human cancer therapy |
| Q38042630 | Therapeutic strategies for head and neck cancer based on p53 status |
| Q89723364 | Therapeutic targeting of TP53-mutated acute myeloid leukemia by inhibiting HIF-1α with echinomycin |
| Q47742599 | Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others |
| Q45878720 | Trans-membrane peptide therapy for malignant glioma by use of a peptide derived from the MDM2 binding site of p53. |
| Q24796110 | Treatment of terminal peritoneal carcinomatosis by a transducible p53-activating peptide |
| Q45864999 | Tumour regression in a ligand inducible manner mediated by a chimeric tumour suppressor derived from p53. |
| Q33807787 | Twenty years of p53 research: structural and functional aspects of the p53 protein |
| Q36905702 | Use of a novel cytotoxic HEXIM1 peptide in the directed breast cancer therapy. |
| Q33511752 | p53 Amino-terminus region (1-125) stabilizes and restores heat denatured p53 wild phenotype |
| Q38307731 | p53 C-terminal interaction with DNA ends and gaps has opposing effect on specific DNA binding by the core |
| Q33779334 | p53 and chemosensitivity. |
| Q33632282 | p53 and the CNS: tumors and developmental abnormalities |
| Q57929625 | p53 latency – out of the blind alley |
| Q29622826 | p53 mutant mice that display early ageing-associated phenotypes |
| Q38069463 | p53 mutations in cancer |
| Q40715545 | p53 requires an intact C-terminal domain for DNA binding and transactivation |
| Q28478414 | p53 transactivation and the impact of mutations, cofactors and small molecules using a simplified yeast-based screening system |
| Q74083357 | p53-dependent apoptosis is regulated by a C-terminally alternatively spliced form of murine p53 |
| Q33545318 | p53-oriented cancer therapies: current progress |
| Q34412182 | αA-Crystallin-derived mini-chaperone modulates stability and function of cataract causing αAG98R-crystallin |
Search more.